TRVI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Dzisiejszy wolumen	64 935.00
Średni wolumen	256 709
Kapitalizacja rynkowa	195.11M
EPS	$0 ( 2024-05-09 )
Następna data zysków	( $-0.110 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.15
ATR14	$0.0120 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Good Jennifer L	Buy	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Stock Option (right to buy)
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)

INSIDER POWER
79.66
Last 98 transactions
Buy: 24 441 332 \| Sell: 1 388 191

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: -0.54 (weak negative)

Signal:(42.223) Neutral

Trevi Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevi Therapeutics Inc Korelacja - Waluta/Towar

0.49
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.58
( weak )

-0.55
( weak negative )

-0.39
( neutral )

Trevi Therapeutics Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Przychody:	$0
Zysk brutto:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Przychody:	$0
Zysk brutto:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.